The sales are too small relative to the $2.5B market cap to signal material insider concern. Monitor the next 8-K for any clinical data readout or pipeline update, likely catalyst for this biotech, but the insider trading itself offers no actionable signal.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $23.97entry
- T+1 · 4mo ago +0.29%α −0.58% · $24.04
- T+5 · 4mo ago +3.00%α +2.07% · $24.69
- T+20 · 4mo ago −1.63%α −1.21% · $23.58
- T+60 · 7w ago −1.25%α −4.82% · $23.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nurix Therapeutics chief legal and scientific officers sold $688K in stock, including a single-day CLO sale of $581K. The cluster is small relative to the $2.5B market cap (0.03%) and fits a common vesting/exercise pattern, the legal officer exercised 22,016 derivative shares at $0-$8.72 alongside her sales. The dollar value is well below materiality thresholds and the sales pattern is consistent with tax-planning liquidity, not informed bearish conviction.
Key Financial Metrics
Key Facts
- Two C-suite insiders sold a total of ~34,300 shares across two dates
- Total open-market sale value is $688K, or ~0.03% of $2.5B market cap
- CLO exercised 22,016 derivative shares for $60K (mostly non-cash), then sold a portion
- CSO sold 5,400 shares for $108K on June 25
- No 10b5-1 plans or routine pattern data visible, but the structure is typical of vesting-and-sell-to-cover
- Prior 30-day insider activity showed 3 sales totaling $948K, this cluster continues a modest cadence
Financial Impact
Open-market sales of ~$688K, representing ~0.03% of market cap
Risk Factors
- No drug products approved, clinical-stage biotech binary risk
- Cash burn for R&D may require future equity financing, diluting current holders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1783029804676 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers